Skip to main content
. 2007 Dec;150(3):576–584. doi: 10.1111/j.1365-2249.2007.03507.x

Fig. 6.

Fig. 6

Deposition of opsonizing C3 split products on CD55- and/or CD46-deficient tumour cells (measured as common C3d moiety). Tumour cells were transfected with phosphorothioate oligonucleotides (S-ODNs), as indicated in the diagram. Following complement activation by polyclonal tumour-specific antibodies, deposited C3d molecules were quantified by flow cytometry. Data are shown from one representative experiment (of three).